Fig. 5: Patient-derived FGFR2 fusion-positive ICC cell line and organoid models are sensitive to gemcitabine, with additive impairment in viability when combined with FGFR inhibition. | npj Precision Oncology

Fig. 5: Patient-derived FGFR2 fusion-positive ICC cell line and organoid models are sensitive to gemcitabine, with additive impairment in viability when combined with FGFR inhibition.

From: Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies

Fig. 5

A GI50 assay with gemcitabine in the PDC model confirmed the IC50 value to be 15 nM. B GI50 assay with gemcitabine in the PDO model confirmed the IC50 value to be 2 nM. C Gemcitabine and pemigatinib have additive effects on viability in the PDC model based on MacSynergy II calculation (95% confidence interval). Results are color-coded for range of synergy from purple (least synergistic) to dark red (most synergistic). Data below the 0 plane are antagonistic, in the plane are additive, and above the plane are synergistic. D Dose–response curves confirm additive effects of gemcitabine in the PDC model when combined with different concentrations of pemigatinib. All curves are normalized to 0 nM gemcitabine under the corresponding concentrations of pemigatinib. E Gemcitabine and pemigatinib have additive effects on viability in the PDO model based on MacSynergy II calculation (95% confidence interval). Data are represented as in C. F Dose–response curves confirm additive effects of gemcitabine in the PDO model when combined with different concentrations of pemigatinib (normalized as per D). Viability results are normalized to DMSO control and presented as the mean +/− standard deviation (error bars) for three biologically independent replicates.

Back to article page